Evidence map›Paper›PMID 34415391›Full record

ReviewApplied microbiology and biotechnology2021

Biotechnological processes to obtain bioactive secondary metabolites from some Mexican medicinal plants.

Mariana Zuleima Pérez-González, María Adelina Jiménez-Arellanes

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Obtaining 2,3-Dihydrobenzofuran and 3-Epilupeol fromMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mariana Zuleima Pérez-GonzálezUnidad de Investigación Médica en Farmacología, UMAE Hospital de Especialiades, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Av. Cuauhtémoc 330, Col. Doctores; Alcaldía Cuauhtémoc 06720, Mexico City, CdMx, Mexico.
María Adelina Jiménez-ArellanesUnidad de Investigación Médica en Farmacología, UMAE Hospital de Especialiades, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Av. Cuauhtémoc 330, Col. Doctores; Alcaldía Cuauhtémoc 06720, Mexico City, CdMx, Mexico. adelinajim08@prodigy.net.mx.ORCID http://orcid.org/0000-0002-9379-5601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consumption of medicinal plants has increased in recent decades due to the fact that they biosynthesize compounds with many biological activities; thus, some plant species with biological potential are being utilized as raw material by the industries for preparation of drugs, phytodrugs, or food supplements. This has the consequence of overexploitation and deforestation, which endangers plant species-of-interest. In recent years, alternatives have been sought to eradicate this problem. A solution that was given and is maintained is plant biotechnology, which favors the production of secondary metabolites (SMt) with important biological activity. Plant biotechnology allows us to increase the yield of a compound-of-interest, reduces its production times and costs, and allows constant and controlled production of the raw material, while aiding in the protection of medicinal plants that are found in danger of extinction. In the scientific literature, procuring the SMt by means of biotechnological processes is described, highlighting the study of five species from Mexican traditional medicine (Lopezia racemosa, Galphimia glauca, Cnidoscolus chayamansa, and Buddleja cordata), and the main biological activities are as follows: anti-inflammatory, hepatoprotector, neuroprotector, anxiolytic, antitumoral, antibacterial, and antioxidant, among others. KEY POINTS: • Secondary metabolites produce by biotechnology processes • Active secondary metabolites isolated from Mexican medicinal plants • Recent advances on the production of some bioactive secondary metabolites.

Indexed as

Plants, MedicinalAnti-Inflammatory AgentsAntioxidantsBiotechnologyMedicine, TraditionalPlant ExtractsAnti-Inflammatory AgentsAntioxidantsPlant ExtractsBioactive compoundsBiotechnology processesMexican medicinal plantsSecondary metabolites

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.